About NVIGEN
NVIGEN is a company based in Sunnyvale (United States) founded in 2011.. NVIGEN has raised $2.23 million across 4 funding rounds from investors including NIH, HHS and Danen Ventures. The company has 8 employees as of December 31, 2022. NVIGEN offers products and services including NVIGEN X™, MagVigen™, NERNST-Seq™, and On-Bead ELISA Kit. NVIGEN operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Sunnyvale, United States
- Employees 8 as on 31 Dec, 2022
-
Sectors
HealthcareTechnology Chemicals & Materials
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nvigen
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.23 M (USD)
in 4 rounds
-
Latest Funding Round
$1.12 M (USD), Seed
Mar 18, 2014
-
Investors
NIH
& 4 more
-
Employee Count
8
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NVIGEN
NVIGEN offers a comprehensive portfolio of products and services, including NVIGEN X™, MagVigen™, NERNST-Seq™, and On-Bead ELISA Kit. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
NGS and multiomics test for early cancer recurrence prediction.
Tools for DNA extraction and purification in diagnostics.
Enhanced single cell RNA sequencing with spatial resolution.
Nanoparticle-based ELISA for sensitive protein biomarker detection.
Unlock access to complete
Unlock access to complete
Funding Insights of NVIGEN
NVIGEN has successfully raised a total of $2.23M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $1.12 million completed in March 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Seed — $1.1M
-
First Round
First Round
(01 Jun 2012)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2014 | Amount | Seed - NVIGEN | Valuation |
investors |
|
| Feb, 2014 | Amount | Seed - NVIGEN | Valuation | Danen Ventures , TSVC |
|
| Sep, 2012 | Amount | Grant - NVIGEN | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NVIGEN
NVIGEN has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Danen Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Chinese venture fund in Silicon Valley
|
Founded Year | Domain | Location | |
|
Investments are directed toward seed-stage startups by CRCM Ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NVIGEN
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NVIGEN
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nvigen Comparisons
Competitors of NVIGEN
NVIGEN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about NVIGEN
When was NVIGEN founded?
NVIGEN was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Where is NVIGEN located?
NVIGEN is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Who is the current CEO of NVIGEN?
Aihua Fu is the current CEO of NVIGEN.
Is NVIGEN a funded company?
NVIGEN is a funded company, having raised a total of $2.23M across 4 funding rounds to date. The company's 1st funding round was a Grant of $201.16K, raised on Jun 01, 2012.
How many employees does NVIGEN have?
As of Dec 31, 2022, the latest employee count at NVIGEN is 8.
What does NVIGEN do?
NVIGEN was established in 2011 in Sunnyvale, United States, within the biotechnology sector focused on nanomaterials. Operations center on the development and provision of nanoparticle reagents, such as magnetic and fluorescent magnetic beads, alongside services like antibody purification and immunoprecipitation assays. These offerings support research into disease understanding, diagnosis, and treatment, with activities conducted primarily in the U.S.
Who are the top competitors of NVIGEN?
NVIGEN's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does NVIGEN offer?
NVIGEN offers NVIGEN X™, MagVigen™, NERNST-Seq™, and On-Bead ELISA Kit.
Who are NVIGEN's investors?
NVIGEN has 5 investors. Key investors include NIH, HHS, Danen Ventures, TSVC, and CRCM Ventures.